Showing 2321-2330 of 2494 results for "".
- US Plans to Ship First Coronavirus Vaccines Within 24 Hours of FDA Approvalhttps://modernod.com/news/us-plans-to-ship-first-coronavirus-vaccines-within-24-hours-of-fda-approval/2478291/US officials on Wednesday indicated that a COVID-19 vaccine will start to be distributed within about 24 hours after a license or emergency-use authorization (EUA) is issued. Paul Ostrowski, who is overseeing logistics for the US government’s Operation Warp Speed initiative, said that the o
- BVI Introduces Patient Packs Aimed at Helping US Ophthalmologists Bring Patients Backhttps://modernod.com/news/bvi-introduces-patient-packs-aimed-at-helping-us-ophthalmologists-bring-patients-back/2478280/BVI has released a line of Patient Packs to help US ophthalmologists bring patients back to the office and OR with confidence, according to a company news release. Ophthalmologists are seeking to get back to normal and address the backlog of patients whose vision has been negatively impact
- Keeler Partners With Medical Device Maker Olleyeshttps://modernod.com/news/keeler-partners-with-medical-device-maker-olleyes/2478278/Keeler has announced a partnership with Olleyes, a developer of eye care-based office and home-based diagnostic products. Terms of the deal were not disclosed. Olleyes is the maker of VisuALL VRP (Virtual Reality Perimetry), a platform designed for standardized and mobile assessment
- Zeiss Launches “Vision in County” Cataract Development Program in Shandong, Chinahttps://modernod.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/The “Vision in County” Cataract Development Program by Zeiss was officially launched in Shandong, China on September 3, 2020. At the event, the first training base was established in the Affiliated Eye Hospital of
- AstraZeneca Pauses COVID-19 Vaccine Trial Amid Safety Concernhttps://modernod.com/news/astrazeneca-pauses-covid-19-vaccine-trial-amid-safety-concern/2478258/Shares in AstraZeneca fell as much as 6% on Tuesday after the company confirmed that a phase 3 trial of its experimental COVID-19 vaccine AZD1222 has been put on hold due to a possible safety issue. AstraZeneca called the move “a routine action which has to happen whenever there is a potent
- BVI Expands Malosa Single-Use Instrument Range in the UShttps://modernod.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/BVI announced the extension of its Malosa range of single-use ophthalmic instruments in the US. The US Malosa portfolio will now include specialty instruments for use in corneal refractive surgery, complementing the existing single-use product range for cataract, oculoplastic, and office-based pr
- AEYE Health Develops Advanced AI-Based Retinal Screening With Instant Resultshttps://modernod.com/news/aeye-health-develops-advanced-ai-based-retinal-screening-with-instant-results/2478232/AEYE Health has developed an AI-based retinal screening system that provides analysis and diagnostic results within 60 seconds. AEYE Health’s advanced machine learning and artificial intelligence technologies offer instant and accurate screening and analysis of the retina for the det
- Clearside Biomedical Expands Patent Portfolio in the US and Europehttps://modernod.com/news/clearside-biomedical-expands-patent-portfolio-in-the-us-and-europe/2478203/Clearside Biomedical announced the recent issuance of three additional patents in the United States and Europe. The United States Patent and Trademark Office (USPTO) recently granted patent number 10,722,396 to Clearside. This patent covers Clearside’s SCS M
- Kubota Vision Receives Orphan Products Clinical Trial Grant for Stargardt Disease Treatment Candidatehttps://modernod.com/news/kubota-vision-receives-orphan-products-clinical-trials-grants-to-emixustat-for-stargardt-disease/2478187/Kubota Vision announced that the FDA Office of Orphan Products Development (OOPD) has awarded an orphan products clinical trial grant to support the ongoing phase 3 study of emixustat in Stargardt disease. Orphan product clinical trial grants support well-controlled studies that will eithe
- Why Johnson & Johnson is Investing in This Niche Telehealth Startuphttps://modernod.com/news/why-johnson-johnson-is-investing-in-this-niche-telehealth-startup/2478171/Pharmaceutical giant Johnson & Johnson is investing in direct-to-consumer telehealth company Thirty Madison. New York City-based Thirty Madison offers telehealth visits and online prescriptions for drugs for hair loss, migraines and acid reflux, according to a FierceHealthcare